Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
One on one Video Meeting with Invesco Mutual Fund25-05-2022
25-05-2022
Buy Gland Pharma: target of Rs 3770: Sharekhan
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3770 in its research report dated May 20, 2022.21-05-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Audited Financial Results for the Quarter and Financial Year ended March 31, 2022.20-05-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of the investor meetings19-05-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Earnings Call for the quarter and year ended March 31, 202219-05-2022
Earnings Call for Q4FY22 of Gland Pharma
Conference Call with Gland Pharma Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.19-05-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on Q4FY22 Financial Results19-05-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on Q4FY22 Financial Results19-05-2022
Q4FY22 Quarterly Result Announced for Gland Pharma Ltd.
Gland Pharma announced Q4FY22 results: Gland Pharma’s FY22 Revenue grew by 27% to reach Rs 44,007 million with PAT margin of 26% Revenue from operations during the fourth quarter of financial year 2022 grew by 24% as compared to corresponding quarter of the previous year. During fourth quarter, Company has achieved EBITDA growth of 10% compared to same period of last financial year and maintained a healthy EBITDA margin of 35%. The Company’s PAT growth was 10% and margin of 24% during the quarter. Commenting on the results, Mr. Srinivas Sadu, MD & CEO of Gland Pharma said “Our foray into Biosimilar/Biologics CDMO business during FY22 was a key strategic initiative to transform Gland Pharma into a full-fledged CDMO company both in Small and Large Molecules. It positions us for long-term growth and value creation for our stakeholders. We reported a strong revenue growth of 24% for Q4FY22 at Rs 11,030 mn driven by growth across all geographies. On a full-year basis, we delivered revenue of Rs 44,007 mn, a growth of 27% and reported a PAT growth of 22% at Rs 12,117 mn with PAT margin at 26%. Our Gross R&D; spend for the year of Rs 2,273 mn is about 5.2% of revenue. Our investments in R&D; are in line with our strategy to expand our product portfolio into complex injectables, we made 29 ANDA filings during the year up from 20 ANDA filings the previous year. We also started our new R&D; centre to expand our development capabilities during the year.” Result PDF19-05-2022
Gland Pharma Ltd - 543245 - Audited Financial Results For The Year Ended March 31, 2022.
Audited Financial Results for the year ended March 31, 2022.19-05-2022